Abstract Phosphatidylethanol species (PEths) are promising biomarkers of alcohol consumption. Here, we report on the set-up, validation, and application of a novel UHPLC-ESI-MS/MS method for the quantification of PEth 16:0/18:1, PEth 18:1/18:1, and PEth 16:0/16:0 in whole blood (30 μL) and in venous (V, 30 μL) or capillary (C, 3 punches (3 mm)) dried blood spots (DBS). The methods were linear from 10 (LLOQ) to 2000 ng/mL for PEth 16:0/18:1, from 10 (LLOQ) to 1940 ng/mL for PEth 18:1/18:1, and from 19 (LLOQ) to 3872 ng/mL for PEth 16:0/16:0. Extraction efficiencies were higher than 55 % (RSD < 18 %) and matrix effects compensated for by IS were between 77 and 125 % (RSD< 10 %). Accuracy, repeatability, and intermediate precision fulfilled acceptance criteria (bias and RSD below 13 %). Validity of the procedure for determination of PEth 16:0/18:1 in blood was demonstrated by the successful participation in a proficiency test. The quantification of PEths in C-DBS was not significantly influenced by the hematocrit, punch localization, or spot volume. The stability of PEths in V-DBS stored at room temperature was demonstrated up to 6 months. The method was applied to authentic samples (whole blood, V-DBS, and C-DBS) from 50 inpatients in alcohol withdrawal and 50 control volunteers. Applying a cut-off value to detect inpatients at 221 ng/mL for PEth 16:0/18:1 provided no false positive results and a good sensitivity (86 %). Comparison of quantitative results (Bland-Altman plot, Passing-Bablok regression, and Wilcoxon signed rank test) revealed that V-DBS and C-DBS were valid alternatives to venous blood for the detection of alcohol consumption.
Introduction
Phosphatidylethanols (PEths) are a group of abnormal phospholipids formed by the presence of ethanol in cell membranes [1] . They are biomarkers of alcohol consumption [2] present in blood, mainly located in erythrocytes [3] , and in different organs [4] . Up to 48 different PEths have been detected in blood collected in autopsy cases of heavy drinkers [5] . All PEths have a common phosphoethanol head on which two fatty acid chains of variable length and degree of saturation are attached. Although blood analysis from heavy drinkers shows inter-individual variations of the distribution of the different PEths [6] , the predominant species in blood after alcohol consumption are PEth 16:0/18:1 (30-46 %) and PEth 16:0/18:2 (16-28 %) [5] [6] [7] [8] [9] . Other PEths detected are PEth 18:1/18:1 and PEth 18:0/18:2 (identical molecular masses), together accounting for about 11-12 % of total PEths [6, 7] while PEth 16:0/16:0 accounts for about 5 % [6] . The half-life of PEths in whole blood was calculated to be 4.0± 0.7 days [3] . In case of chronic/excessive alcohol Electronic supplementary material The online version of this article (doi:10.1007/s00216-015-9169-1) contains supplementary material, which is available to authorized users.
consumption, PEths are detectable in blood up to 28 days after sobriety [10] . Moreover, quantification of PEths can be used to detect the degree of alcohol consumption as a significant correlation between the PEths concentrations in blood and the amount of consumed ethanol has been demonstrated [11] .
Numerous studies have been published on the quantification of PEths in blood and these have been reviewed in 2012 [10] . The most used extraction technique is a liquid-liquid extraction (LLE) with hexane [5] [6] [7] [11] [12] [13] [14] [15] [16] [17] (or heptane [8] ) after stepwise addition of blood to isopropanol and the internal standard (IS) solution. Some methods added water [6] , borate buffer pH 9 [5] , or sodium acetate buffer pH 5 [15] to dilute the blood. Some publications reported other types of sample preparation, such as protein precipitation with methanol [18] or protein precipitation followed by an online-solid phase extraction [19] . A number of detection methods is based on HPLC with normal phase columns coupled to lightscattering detection (ELSD); chromatography has been carried out with hexane and propanol-based gradients containing acetic acid and triethylamine [3, 4, 11, 12] . Quantification limits (LLOQ) obtained with these methods ranged between 100 and 500 ng/mL [4, 11] , analyzing 250 to 300 μL of whole blood. PEths have also been analyzed with non-aqueous capillary electrophoresis (CE) coupled to UV [13] detection. Both HPLC-ELSD and CE-UV [13] methods measure the total amount of PEths. However, LC methods coupled to MS/MS detection allow to obtain much lower LLOQs (between 0.7 and 83 ng/mL, based on the analysis of between 100 and 300 μL of whole blood) and are able to identify and quantify individual molecular species [6-8, 15, 18-20] .
To improve the stability of compounds in whole blood and to facilitate the storage and transportation of samples [21] , DBS methods have been developed. Numerous DBS-based methods have been published for a wide variety of applications, including therapeutic drug monitoring and toxicology [22] . Also alcohol markers such as ethyl glucuronide, ethyl sulfate, and PEths have been determined, starting from DBS ( [15, 18, 21, [23] [24] [25] ; reviewed by Sadones et al., 2014 [26] ). Since 2011, two publications have reported on the quantification of PEth 16:0/18:1 [15, 18] and PEth 18:1/18:1 [15] in V-DBS samples, while only one [21] reported on the analysis of C-DBS samples (detection of PEth 16:0/18:1 in newborns to detect prenatal alcohol exposure). V-DBS are prepared by spotting a fixed volume of venous blood onto a filter paper, whereas C-DBS are generated by direct collection of blood drops appearing after a finger or heel prick onto a filter paper. C-DBS offer the advantage compared to venipuncture of being less invasive and not requiring the service of nurses or physicians. Since these are typically collected in a nonvolumetric way, these samples are mostly processed by excising punches with a fixed diameter from the global spot. This partial-spot approach requires the assessment of the impact of variables such as hematocrit, punch localization, and spot volume on the quantitative result [27, 28] .
In this paper, we present the validation of UHPLC-ESI-MS/MS methods for the quantification of three PEths (PEth 16:0/18:1, PEth 18:1/18:1 and PEth 16:0/16:0) in whole blood, V-DBS, and C-DBS according to international guidelines [29] and published recommendations [27] . To our knowledge, this is the first report on the rigorous validation of the differences between capillary and venous DBS including the impact of specific parameters such as the influence of hematocrit, punch localization, and spot volume on PEths. In addition, a sensitive method for PEth 16:0/16:0 in DBSs was developed and stability of the three species in V-DBS was evaluated over a period of 6 months. Moreover, successful participation to a proficiency test demonstrated the validity of the method for blood (no proficiency tests for DBS are available). Finally, the developed methods were applied to evaluate the agreement between the quantitative results from the analysis of whole blood, V-DBS and C-DBS obtained from 100 volunteers (inpatients in alcohol withdrawal and control volunteers). Receiver operating characteristic (ROC) curves performed on these results allow us to propose a possible cut-off value to detect chronic and excessive alcohol consumption. It was our main objective to investigate whether C-DBS could be a reliable alternative for the detection of PEths in whole blood, as this could lead to a more user friendly and practical approach to detect excessive and chronic alcohol consumption.
Materials and methods

Chemicals
1,2-Dioleoyl-sn-glycero-3-phosphoethanol (sodium salt; PEth 18:1/18:1), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanol (sodium salt; PEth 16:0/16:0) were obtained from Avanti Polar Lipids (Alabaster, Alabama, USA). Palmitoyl-2-oleoyl-snglycero-3-phosphoethanol (PEth 16:0/18:1) was purchased from Enzo Life Sciences (Antwerp, Belgium). As deuterated analogues have not been commercialized yet, four different internal standards from Avanti Polar Lipids were evaluated during validation: 1,2-dipalmitoyl-sn-glycero-3-phosphomethanol (sodium salt; PMeth 16:0/16:0; IS), 1,2-dioleoyl-sn-glycero-3-phosphomethanol (sodium salt; PMeth 1 8 : 1 / 1 8 : 1 ; I S ) , 1 , 2 -d i p a l m i t o y l -s n -g l y c e r o -3 -phosphopropanol (sodium salt; PProp 16:0/16:0; IS), and 1, 2-dioleoyl-sn-glycero-3-phosphopropanol (sodium salt; PProp 18:1/18:1; IS).
Isopropanol (ULC/MS), tetrahydrofuran (ULC/MS), ammonium acetate (ULC/MS), water (HPLC), and methanol (ULC/MS) were purchased from Biosolve (Valkenswaard, The Netherlands). Isopropanol and n-hexane, gradient grade for liquid chromatography, were purchased from Merck KGaA (Darmstadt, Germany). Formic acid for mass spectrometry (∼98 %) was purchased from Sigma-Aldrich (Steinheim, Germany).
Standard solutions, calibrators, and quality control samples
Stock solutions of PEths (PEth 16:0/18:1 (1.000 mg/mL), PEth 18:1/18:1 (0.970 mg/mL) and PEth 16:0/16:0 (0.968 mg/mL)) and stock solutions of the 4 evaluated ISs (PMeth 16:0/16:0 (0.968 mg/mL), PMeth 18:1/18:1 (0.971 mg/mL), PProp 16:0/16:0 (0.969 mg/mL) and PProp 18:1/18:1 (0.971 mg/mL)) were prepared in methanol. A calibrator working solution (100 μg/mL), a quality control (QC) working solution (50 μg/mL) and an IS working solution (5 μg/mL) for the blood and V-DBS methods were prepared by diluting the stock solutions in methanol. For the C-DBS method, a calibrator working solution of 250 μg/mL, a QC working solution of 250 μg/mL and an IS working solution of 0.25 μg/mL were prepared in methanol. All working solutions were stored at −18°C.
Daily dilutions of IS working solutions were performed in solution A, consisting of isopropanol, 10 mM ammonium acetate buffer and formic acid (6:4:0.2, v/v), to reach a concentration of 100 ng/mL (used for the whole blood and V-DBS method) and 10 ng/mL (used for the C-DBS method).
Daily dilutions of calibrator working solutions and QC working solutions were performed in water to obtain eight different concentrations for calibrators and three for QCs. A second dilution was performed in EDTA blank whole blood (see Electronic Supplementary Material (ESM) Tables S1 and S2). Final calibrator concentrations in blood were between 10 and 2000 ng/mL for PEth 16:0/18:1, 10 and 1940 ng/mL for PEth 18:1/18:1, and between 19 and 3872 ng/mL for PEth 16:0/16:0. For the two DBS methods, 30 μL of calibrators and QCs in blood were spotted onto Whatman 903 filter paper (GE Healthcare). Spots were dried for a minimum of 2 h at room temperature. The complete DBS was used for the V-DBS method and three punches (3 mm) were used for the C-DBS method, unless indicated otherwise. Here, we typically used three punches from the same DBS, except in the application study, where not from all C-DBS three 3-mm punches could be obtained. The hematocrit of the blood used to prepare the DBS calibrators was 0.48±0.02, as measured using a Sysmex XP-300™ automated hematology analyzer (Sysmex America, Inc.).
Sample preparation
PEths were extracted by LLE with n-hexane. For the whole blood method, 30 μL of the sample was added to a 5 mL disposable glass tube containing 250 μL of solution A (consisting of isopropanol, 10 mM ammonium acetate buffer and formic acid (6:4:0.2, v/v)) and 50 μL of the IS solution (100 ng/mL). After a quick mixing (vortex), 1 mL n-hexane was added and the sample was gently mixed for 10 min. The tubes were centrifuged (10 min, 14,000 rpm (20,800 x g), 4°C) and the clear supernatant was transferred to a total recovery glass vial (Waters, Zellik, Belgium) and evaporated to dryness during 30 min in a rotational vacuum concentrator (RVC 2-33 IR, Martin Christ, Osterode am Harz, Germany). The final dried extract was dissolved in 250 μL of a solution B (50 % of mobile phase A and 50 % of mobile phase B, see below).
For the V-DBS method, the complete DBS (30 μL) was excised and placed in a 5 mL disposable glass tube containing 250 μL of solution A and 50 μL of the IS solution (100 ng/ mL). For the C-DBS method, three (or one, where indicated) punches (3 mm) were excised from the DBS and placed in a 5 mL disposable glass tube containing 250 μL of solution A and 50 μL of the IS solution (10 ng/mL). For both DBS methods, the tubes were gently mixed for 1 h. After adding 1 mL of n-hexane, the samples were mixed for another 10 min. After centrifugation, the clear supernatant was transferred in total recovery glass vials and evaporated to dryness. The final dried extract was dissolved in 250 μL of solution B for the V-DBS and in 100 μL of solution B for the C-DBS.
For the whole blood method and the V-DBS method, 5 μL was injected in partial loop with needle overfill mode. For the C-DBS method, 10 μL was injected in full loop mode.
Liquid chromatographic and mass spectrometric conditions
Analyses were performed on an Aquity UPLC® system coupled to a Xevo TQ S tandem mass spectrometer (Waters, Manchester, UK) equipped with an electrospray ionization source operated in negative mode. The compounds were separated on an Acquity UPLC® BEH C8 (2.1×50 mm, 1.7 μm) column (Waters) using as mobile phase A 10 mM ammonium acetate buffer with 0.05 % formic acid (pH 2) and as mobile phase B isopropanol with 10 % of tetrahydrofuran at a flow rate of 400 μL/min. The gradient elution started with 40 % of mobile phase A and decreased to 0 % of mobile phase A at 1.5 min. The washing step, containing 100 % of solution B, was held for 1 min and was followed by 1 min re-equilibration with the starting condition, resulting in a total run time of 3.5 min. The column temperature was set at 60°C.
For the MS/MS detection, the following parameters were used: temperature of source gas (nitrogen) was 150°C, desolvatation gas (nitrogen) flow was 1000 L/h at 650°C, capillary voltage was 3 KV, cone voltage was 10 V with a cone gas flow at 150 L/h and collision gas (argon) flow was 0.15 mL/min. Detection was performed in the multiple reaction monitoring mode (MRM). Two transitions were 
Method validation
Selectivity, sensitivity, matrix effect, extraction efficiency, limit of quantification, linearity, accuracy and stability were evaluated based upon international guidelines [29] . The influence of hematocrit, punch localization and spot volume were evaluated for the C-DBS method [27, 28] .
To study endogenous interferences, six blank whole blood samples from different teetotallers were analyzed. To verify that IS compounds do not interact with PEths, two zero samples (blank samples spiked with IS solution) were analyzed. According to the EMA guideline, in our method interferences are acceptable as long as the signal was lower than 20 % of the response at the LLOQ [30] .
Matrix effect was quantified and evaluated by the postextraction addition technique using six different blank bloods from teetotallers [31] . Whole blood (30 μL), V-DBS (complete 30 μL DBS), and C-DBS (three filter paper punches spiked each with 3.5 μL of whole blood) were extracted. The reference standards and IS (diluted in the mobile phase) were added in the total recovery vial before the injection. These samples were compared with control samples spiked at the same theoretical concentration in the mobile phase. Extraction efficiency was evaluated by comparing responses of six blank samples spiked before sample preparation with responses of six blank samples, where the reference standards were spiked after the sample preparation in the mobile phase. Matrix effect and extraction efficiency were evaluated at low, medium, and high concentrations. For the C-DBS method, blood samples with varying hematocrit levels (measured from 0.31 to 0.58) were used, to study the influence of the hematocrit variation on the extraction efficiency and on the matrix effect.
The lower limit of quantification (LLOQ) is the lowest concentration of analyte with a signal-to-noise ratio greater than 10/1 for both transitions and for which the bias and precision deviation is less than 20 %.
Calibration model and weighting factor were evaluated for each compound and each method. The linearity was tested by performing F tests (α=0.05). Homoscedasticity was tested visually by plotting residuals vs. fitted value. In case of heteroscedasticity, a weighted regression (1/x and 1/x 2 ) was applied (slope and intercept). The sum of relative errors (difference between the calculated concentration and its nominal concentration) for each model was calculated and plotted against the nominal concentrations. The model with a R 2 ≥ 0.99 with the lowest sum of relative errors was selected. The goodness of fit of the selected model was tested, calculating the relative errors for calibrators and QCs. The relative errors should be lower than 15 % except for the LLOQ (<20 %) [30] .
Three internal QCs spiked at low, medium, and high concentration, were analyzed in duplicate on eight different days to assess accuracy (bias) and precision (repeatability and intermediate precision). A single-factor ANOVA test with significance level (α) of 0.05 allows calculating bias, repeatability and intermediate precision with these data, with acceptance criteria of 15 % (20 % for the LLOQ). The measurement uncertainty was also calculated (2.12×RSD t ) and used to interpret quantitative results close to the LLOQ or close to the cut-off value.
The validity of the PEth 16:0/18:1 quantification in blood was tested by participation to a proficiency test organized by Equalis (Uppsala, Sweden).
Processed sample stability and long term storage stability were evaluated at low and high concentrations for the whole blood method and for the V-DBS method. The mean response of the stability samples should be within 90-110 % of the mean response of the control samples and the 90 % confidence interval of the stability sample responses should be within ±20 % of the control sample responses.
The influence of the hematocrit on the response was evaluated for five hematocrit values at low and high concentrations. Blank blood samples with variable hematocrit level were prepared by adding or removing plasma to EDTA blank blood samples. The measured hematocrit values were 0.39, 0.42, 0.48, 0.50, and 0.57. Six spots per concentration and per hematocrit level were prepared and single centrally located punches were analyzed. Measured responses were compared with a one-way ANOVA test (α=0.05). To evaluate whether no artefactual results were obtained because spiked samples might behave differently from real samples (where PEth species are presumably located in erythrocytes), we set-up an experiment in which blood with different hematocrit was prepared from blood of two inpatients. More specifically, 200 μL of blood of an inpatient was diluted with plasma (between 25 and 200 μL) and erythrocytes (between 0 and 175 μL) of an alcohol abstainer to generate six blood samples of 400 μL with a different hematocrit (with measured hematocrits between 0.20 and 0.60) but with the same PEths concentrations (PEths virtually exclusively being derived from the 200 μL of inpatient blood). This blood was used to generate DBS, which were processed as real samples (see sample preparation section). The DBS analysis was performed in quadruplicate at each hematocrit level. Also the blood PEths concentrations were determined and served as a reference.
The influence of the punch localization (peripherally or centrally) was evaluated at low and high concentrations and at low (0.39), intermediate (0.48) and high (0.57) hematocrit levels. Six spots per concentration and per hematocrit level were prepared and the responses measured in peripherally and centrally located punches (one central and one peripheral punch were analyzed per DBS) were compared using a oneway ANOVA test (α=0.05).
Three blood spot volumes (20, 35 , 50 μL) were tested at low (0.32), intermediate (0.48), and high (0.67) hematocrit levels and at two concentrations: low and high. Six spots per concentration and per hematocrit level were prepared and centrally located 3 mm punches (1/DBS) were analyzed. Responses were compared using a one-way ANOVA test (α= 0.05) to detect significant differences.
The normality of the distributions and the homogeneity of variances were tested using the Shapiro-Wilk test and the Levene's test prior to one-way ANOVA tests [32] .
Application to a comparative study
Sample collection
Whole blood and C-DBS from inpatients in alcohol withdrawal were collected at the Brugmann Hospital (Brussels, Belgium) one business day after their admission. Whole blood and C-DBS from control volunteers were collected by the medical staff of the Military Hospital in Brussels (Belgium). The inpatients group was composed of 37 males and 13 females, between 27 and 71 years (mean=47, median=47) and with a self-reported number of abstinence days before the sampling between 1 and 21 (mean=4, median=2). The control group was composed of 23 males and 27 females, between 22 and 64 years (mean=40, median=37) and with a selfreported mean alcohol consumption per week between 0 and 16 units (mean=5, median=6). Seven out of the 50 control volunteers were teetotallers.
Venous whole blood samples were collected in a 4 mL EDTA tube and were stored at −80°C until analysis. Five C-DBS were collected onto a Whatman 903 filter paper card after a fingertip prick with a contact-activated lancet (BD Microtainer®, Becton Dickinson). Five V-DBS were prepared from the EDTA tubes by pipetting 30 μL of venous blood onto a filter paper. C-DBS and V-DBS were left to dry for minimum 2 h at room temperature and were then stored in zipclosure plastic bags containing a desiccant packet (SigmaAldrich) at room temperature until the analysis.
The study protocol was approved by the ethics committee of the Brugmann Hospital (Brussels, Belgium) and informed consent was obtained from each subject before enrolment in the study (B077201420445).
Statistical analysis
Bland-Altman plot, Passing-Bablok regression analysis, and Wilcoxon signed rank test were used to study the agreement between quantitative results obtained from whole blood, V-DBS, and C-DBS samples [33] . A Bland-Altman plot is used to assess the absence of systematic differences between two measurements. The mean of the two measurements is plotted against the difference between these, 95 % of the differences are expected to lie within the limits of agreement (mean±1.96 SD). The Passing-Bablok regression analysis is a scatter diagram of the concentrations obtained with two different methods. The regression line and equation are used to detect measurement errors. No proportional differences are observed as long as the 95 % confidence interval of the slope includes 1 and no systematic differences are observed as long as the 95 % confidence interval of the intercept includes the zero value. Wilcoxon signed rank test was performed to detect significant differences (p value<0.05) between the concentrations obtained from two methods.
ROC curve analyses were performed to determine optimal cut-off values (higher sensitivity with 0 false positive results) to distinguish between inpatients in alcohol withdrawal and control volunteers. The area under the curve (AUROC) was used to quantify the overall ability of the method to discriminate between the two populations. A perfect diagnostic method (0 false positives and 0 false negatives) will have an area of 1, where a method with no diagnostic ability will have an area of 0.5.
Results
Method Validation
Linearity, LLOQ, matrix effects, extraction efficiency, selectivity, sensitivity and accuracy were assessed for the three methods. Stability was tested for the whole blood and V-DBS methods. For the C-DBS method, the impact of hematocrit, punch localization, and blood spot volume were evaluated.
The Table 2 .
In summary, no interfering peaks were detected in blank samples and the addition of the IS did not interfere with PEths detection. The recovery was between 66 and 100 % (RSD< 18 %) for the blood method, between 55 and 63 % (RSD< 14 %) for the V-DBS method and between 61 and 78 % (RSD <15 %) for the C-DBS method. Visual inspection of the results indicated no influence of the hematocrit level on extraction efficiency (Fig. 1) .
The bias (%), repeatability (%RSD r ), and intermediate precision (%RSD t ) were less than 13 % for whole blood, V-DBS, and C-DBS methods. The maximal uncertainties of measurement (2.12 × RSD t ) were 23 % The validity of the quantification of PEth 16:0/18:1 in blood was demonstrated by the successful participation (z score<2) to a proficiency test. The z score obtained ((reported value−target value)/SD) was 0.11 for sample B (reported value=2.52 μmol/L, target value= 2.50 μmol/L, SD=0.23, N=8) and 1.43 for sample C (reported value=0.17 μmol/L, target value=0.16 μmol/ L, SD=0.01, N=8). The samples were used to create V-DBS and z scores of 0.38 for sample B (measured value=2.59 μmol/L) and 0.22 for sample C (measured value=0.16 μmol/L) were calculated ((measured value−target value)/SD). PEths were not detected in sample A (reported value < LLOQ). Sample A was whole blood from a teetotaller.
All samples were stable in the autosampler for 72 h. PEths were stable up to 6 months when stored at −80°C in EDTA tubes. PEth 16:0/18:1 and PEth 18:1/18:1 were stable during 6 months in V-DBS samples stored at room temperature in zip-closure plastic bags containing a desiccant packet. The 90 % confidence interval of the stability sample responses for PEth 16:0/16:0 in V-DBS were within ±20 % of the control sample responses, although the mean response of the high stability samples was 119 % of the mean response of the control samples.
No significant differences (p>0.05) were observed between the mean responses obtained for the analysis of V-DBS samples spiked with PEths reference standard, prepared from blood with hematocrit levels spanning a normal to high range (0.39, 0.42, 0.48, 0.50, 0.57). In addition, varying the hematocrit level (between 0.20 and 0.60) of real inpatients' blood samples (by adding blank plasma and red blood cells) did not adversely affect quantification, as demonstrated in Fig. 2 , which depicts the bias when comparing results obtained from DBS with those obtained from blood. Similar mean responses were (10) 102 (5) 88 (3) 115 (6) 117 (6) 118 (5) 103 (4) 102 (7) 101 (5) ME PMeth 16:0/16:0 (RSD%) ME PMeth 16:0/16:0 (RSD%) ME PMeth 16:0/16:0 (RSD%) 81 (11) 67 (8) 57 (10) 80 (6) 77 (9) 76 (7) 72 (5) 66 (7) 65 (6) ME (10) 101 (5) 91 (3) 118 (6) 116 (6) 122 (4) 105 (4) 100 (7) 104 (3) V-DBS ME (%) RSD (%) V-DBS ME (%) RSD (%) V-DBS ME (%) RSD (%) 137 (9) 99 (9) 76 (8) 121 (6) 97 (5) 94 (6) 110 (9) 81 (11) 84 (6) ME (6) 108 (4) 87 (3) 110 (5) 107 (4) 108 (2) 102 (8) 89 (9) 96 (5) C-DBS ME (%) RSD (%) C-DBS ME (%) RSD (%) C-DBS ME (%) RSD (%) 101 (15) 79 (17) 68 (20) 106 (11) 89 (12) 73 (12) 107 (9) 69 (16) 59 (20) ME (6) 89 (4) 89 (3) 114 (4) 101 (3) 97 (8) 116 (7) 78 (3) 77 (5) obtained from Bias % Bias % Bias % LLOQ 3 Concentrations measured in whole blood, V-DBS and C-DBS from all study participants were compared using BlandAltman plot, Passing-Bablok regression analysis, and Wilcoxon signed rank test.
PEth 16:0/18:1 was quantified (>LLOQ) in 50/50 inpatients and in 18/50 control volunteers. Concentrations measured in blood ranged from 16 to more than 2000 ng/mL (mean=1232, median=1087) in alcoholics and were between 13 and 220 ng/mL (mean=59, median=49) in control volunteers with a quantifiable result. PEth 18:1/18:1, with blood concentrations ranging from 17 to 307 ng/mL (mean=101, median=78), was measured in 47/50 inpatients and in 1/50 control volunteers (17 ng/mL). PEth 16:0/16:0 was quantified only in some inpatient samples (34/50) with concentrations varying from 25 to 203 ng/mL (mean=97, median=89). An overview is given in Figs. 4 and 5 .
In the comparison of the results obtained from blood, C-DBS, and V-DBS, correlation coefficients exceeded 0.995 for PEth 16:0/18:1 (N=68), 0.978 for PEth 18:1/18:1 (N=48), and 0.962 for PEth 16:0/16:0 (N=32). As shown in Fig. 3 (right) and reported in Table 3 (presenting the numerical results), the mean % differences in the concentration between venous blood and C-DBS included the 0 value for the three PEths. The 95 % confidence intervals of the slope obtained from the Passing-Bablok regression analysis included or were very close to 1 and the 95 % confidence intervals of the intercept included the 0 value (Fig. 3, left and Table 3 ). No significant differences (p≥0.05) in the mean measured concentrations were detected using Wilcoxon signed rank test. The same comparisons were performed between blood and V-DBS and between V-DBS and C-DBS for the three compounds (Table 3 and ESM Figs. S2 and S3), with essentially the same conclusions. Only in three cases with measurable (i.e., above LLOQ) PEth 16:0/16:0 in whole blood, V-DBS and C-DBS, a discrepancy was observed, when taking into account the measurement uncertainty at the LLOQ. The blood, V-DBS and C-DBS concentrations in these three cases were respectively 32, 23* and 25 ng/mL (case 1), 22*, 31 and 21* ng/mL (case 2) and 27, 29 and 22* ng/mL (case 3). For four quantitative results (indicated with an asterisk) in these three cases, the results should actually be considered negative when the measurement uncertainty is taken into account (exemplified in ESM Fig. S4 ). These three cases were not taken into account for the statistical analysis.
Distributions of the concentrations of PEth 16:0/18:1 measured in whole blood, V-DBS and C-DBS from inpatients in alcohol withdrawal and control volunteers are presented in Fig. 4 . For the uncertainty at the cut-off, the uncertainty established at the LLOQ was used study, PMeth 18:1/18:1 compensated best for matrix effect for each compound and was therefore chosen as IS for all three methods.
The detection of PEths requires highly sensitive techniques, due to the low amount of a certain PEth present in the sample (e.g., 16:0/16:0) and/or due to a low amount of sample (e.g., C-DBS). Therefore, special attention was paid to decrease possible ion-suppression by optimizing both the extraction and the chromatographic separation.
Variable recoveries, ranging from 33 % ( [7] , have been reported in past publications using a LLE with a mixture of isopropanol and hexane (2:3, v/v). We have optimized the LLE procedure to extract PEth from venous blood. Therefore, the pH during extraction was adjusted to 2 by adding 2 % formic acid in a mixture of 10 mM ammonium acetate buffer and isopropanol before extraction with hexane. This resulted in a mean extraction efficiency from venous blood of 83 % (RSD=13 %) for PEth 16:0/18:1, 87 % (RSD=13 %) for PEth 18:1/18:1 and 82 % (RSD=20 %) for PEth 16:0/16:0. Somewhat lower percentages were observed (between 55 and 78 %) for the V-DBS and the C-DBS methods. Similar percentages, ranging from 68 to 91 % [15] and 56 to 76 % for PEth 16:0/18:1 [18] and from 27 to 43 % for PEth 18:1/18:1 [15] , were reported earlier for other DBS-based methods. The basis for this somewhat lower extraction efficiency is not known. Interaction with the filter paper might be a possibility, as recently suggested by Koster et al. for immunosuppressants [34] .
Reversed-phase LC separation is the method of choice for the identification and quantification of phosphatidylethanol species. The retention is based on the lipophilicity, determined by the length and number of double bonds present in the fatty acid side chains [35] . Because the nonpolar part of PEths tends to interact very strongly with the nonpolar hydrocarbon phase of a reversed-phase column, the use of a more polar phase (i.e., C8 [14, 18, 20] , C4 [7, 15] or phenyl [16] ) instead of a C18 phase allows to decrease the retention of PEths [14] . The use of less polar solvents, such as tetrahydrofuran (index polarity=4.0), isopropanol (index polarity=3.9) or methanol (index polarity=5.1) instead of acetonitrile (index polarity=5.8) also improved the elution of PEths using a reversed-phase column. In our methods, gradient elution based on an ammonium acetate buffer and a mixture of 10 % tetrahydrofuran in isopropanol on a 50-mm C8 column was chosen.
Our While it seems at first sight that our method is less sensitive, the most sensitive method Fig. S1 ). In addition, no influence of the hematocrit on matrix effect and extraction efficiency was observed ( Fig. 1 ) and quantification was not affected when comparing DBS and blood concentrations in real samples with a wide hematocrit range (Fig. 2 ). An important advantage of DBS compared with venous blood is the improvement of analyte stability, avoiding the degradation of PEths in venous blood not stored at −80°C [24] and the post-collection synthesis of PEths in samples exposed to ethanol [18] . Helander et al. have demonstrated that PEths were stable in venous blood, if stored at −80°C, and this up to 14 months [7] . A decrease of the concentration of PEth 18:1/18:1 (18 %) and PEth 16:0/18:1 (25 %) has been described for EDTA whole blood samples stored at −20°C for 30 days [24] . Stability of PEth in DBS (at −20°C and 20°C) has been assessed up to 30 days by Faller et al. [24] . Our results confirm the stability of PEths in blood stored at −80°C and, more importantly, demonstrate that PEths were stable in DBS samples stored in zip-closure plastic bags containing a desiccant packet at room temperature for up to 6 months, although a slight bias (119 %) was observed for PEth16:0/16:0 in the QC high.
Finally, the successful participation (z scores<1.43) to an international proficiency test organized by Equalis (Uppsala, Sweden) proved that the venous blood method for the quantification of PEth 16:0/18:1 is accurate.
A hundred authentic samples (50 inpatients in alcohol withdrawal and 50 control volunteers) were analyzed using our three methods. To ensure C-DBS method validity, the hematocrit level of inpatients in withdrawal therapy (N=48) was measured and ranged between 0.33 and 0.49 (mean= 0.43, median=0.44), with 83 % (40/48) of the inpatient hematocrit levels lying within the reference range [28, 36] (0.41-0.50 for men and 0.36-0.44 for women).
Comparisons of the PEths concentrations measured using the three assays (Table 3) have shown limits of agreement of less than 33.62 %, with no significant differences using Wilcoxon signed rank test analyses (p≥0.05) and BlandAltman analyses (mean differences<2.82 %, with the zero value included in the 95 % CI). Passing-Bablok regressions indicated a good overall correlation (R>0.962), no systematic differences (95 % CI of the intercept values include the zero value) and no proportional differences, although 1 was just not included in the 95 % CI of the slope in 3 out of 9 comparisons. In literature, agreement between venous blood and V-DBS concentrations has been assessed using Bland-Altman analysis for PEth 18:1/18:1 and PEth 16:0/18:1 [15, 18] . One study showed good agreement, with a mean difference of 95.8 ng/ mL (RSD=3.0 %) and −4.3 ng/mL (RSD=2.9 %) for PEth 16:0/18:1 and PEth 18:1/18:1, respectively [15] . Another study, despite a limit of agreement of more than 50 %, reported no significant bias (mean −4.5 %; RSD=33.8 %) for PEth 16:0/18:1 and a good correlation (R=0.94) when comparing 281 results obtained from the analysis of venous blood and of three punches excised from V-DBS [18] . Both studies concluded that PEth 16:0/18:1 and 18:1/18:1 in V-DBS were a useful tool to monitor alcohol misuse. Our population study not only confirms these conclusions, but also extends these to PEth 16:0/16:0, and, importantly, demonstrates the agreement between blood and C-DBS. The latter is the most relevant comparison, as in real practice, C-DBS will be collected from a fingertip. Thus, the results presented here strongly suggest that C-DBS analysis is a valid alternative to venous blood analysis for the quantification of In literature, HPLC-ELSD methods analyzing total PEths in blood generally used cut-off values between 0.2 and 1 μmol/L [7, 10, 11, 17, 19] to detect alcohol consumption. In Sweden, 0.7 μmol/L of total PEths is used as the clinical threshold [7] . These values were fixed by the LLOQ of the methods used and are limited to the detection of relatively high alcohol consumption (i.e., more than 50 g ethanol per day at an LLOQ of 0.7 μmol/L total PEths [17] ). For PEth 16:0/18:1, an upper reference value for blood donors (N=200) of 141 ng/mL (0.2 μmol/L) has been proposed, which provided 5 % false positive results and 17 samples detected as outliers [8] . In addition, two cut-off values for PEth 16:0/18:1 have been proposed, one of 700 ng/mL to detect problematic drinking [19] and another of 80 ng/mL to detect alcohol consumption (4 drinks daily during 30 days) in patients with liver disease (N=222) [37] . This second proposed cut-off value was selected to improve the sensitivity of the test (91 %), and so provides a lower specificity (77 %), which nevertheless can be improved up to 90 % using a cut-off value of 300 ng/mL [32] .
In our case, we have calculated a cut-off value of 221 ng/ mL in blood to detect chronic and excessive alcohol consumption (inpatients on alcohol withdrawal), based on the highest sensitivity (86 %) which was associated with the absence of false positive results (specificity=100 %). It is of interest to add that three out of the seven inpatients with PEth 16:0/18:1 concentrations lower than the chosen cut-off value declared to have ceased their alcohol consumption 2-3 weeks before the sampling. Importantly, and lending further support to the validity of using C-DBS, is that application of the blood cut-off to the C-DBS and V-DBS data yielded the same sensitivity and specificity. 1 were stable in V-DBS at room temperature for up to 6 months. The quantification of PEths via the C-DBS method was not significantly influenced by the hematocrit, the punch localization or the spot volume. Statistical comparisons (Bland-Altman plot, Passing-Bablok regression analysis, and Wilcoxon signed rank test) of the measured concentrations obtained from venous blood, V-DBS and C-DBS from 100 volunteers (alcoholic inpatients and control volunteers) showed good agreement. Furthermore, application of a cut-off value of 221 ng/mL for PEth 16:0/18:1 to distinguish between inpatients in alcohol withdrawal and control volunteers provided a sensitivity of 86 % and no false positive results (specificity= 100 %). To conclude, the developed method for C-DBS can be of interest to detect high and chronic alcohol consumption, as it offers distinct advantages such as a less invasive blood sample collection, stability during storage and transportation and a relatively simple sample preparation before analysis.
Conclusion
